Vera Therapeutics - October 22 Investor Webcast - VERA THERAPEUTICS INC

Financial Performance:

• No specific Q3 financial metrics (revenue, earnings, margins, cash flow, debt) were disclosed as this call focused on clinical data; Q3 earnings and commercial update for the commercialized product TruTacna (Atacicept) are scheduled for November.
• Commercial launch of TruTacna in the US is proceeding as planned under the July 7th accelerated approval.

Guidance and Future Outlook:

• Regulatory Milestones: Supplemental BLA (sBLA) submission expected this quarter; full FDA approval and label update anticipated by mid-2027.
• Clinical Trial Evolution: ORIGIN-3 trial design (52-week GFR endpoint) has been validated and accepted by the FDA as a paradigm shift, likely setting the standard for future IgAN trials.
• Commercial Inflection: Sales force detailing restricted by current label; full promotion and uptake inflection expected post-full approval in 2027.
• Pipeline Expansion: Data on Atacicept in adolescents with IgAN and in membranous nephropathy (adjacent autoantibody-driven disease) presented at ASN.

Business Segments and Product Lines:

• Primary Product (TruTacna/Atacicept): Successfully completed Phase 3 ORIGIN trial for IgAN; currently transitioning all placebo patients to open-label Atacicept.
• Product Attributes: Weekly subcutaneous injection (150mg) with high patient compliance; targets B-lymphocyte activation cytokine (BLyS) and APRIL.
• Efficacy Metrics: Achieved 5.6 mL/min/year placebo-adjusted GFR protection at Week 52 and 11.1 mL/min/year at Week 104; returned GFR loss to physiological levels (<1 mL/min/year).
• Secondary Outcomes: 76% reduction in composite kidney disease progression; 51-60% reduction in proteinuria; 65-67% reduction in pathogenic IgA; 97% resolution of hematuria.

Market and Competitive Landscape:

• Competitive Context: Compared favorably against Semeprolimab (targeting APRIL only); ORIGIN-3 data validated in a high-risk population, unlike previous trials with lower-risk cohorts.
• Market Shift: Accelerating transition from steroid-based therapy (toxic, short-lived efficacy) to precise immune modulation with Atacicept; steroids expected to become obsolete in IgAN treatment.
• Diagnostic Awareness: Significant push to increase biopsy rates and early diagnosis (currently ~2-2.5 years delay) to prevent irreversible kidney function loss; prevalence of biopsy-proven IgAN in US estimated to be 160k+, potentially underdiagnosed.

Risks and Challenges:

• Trial Integrity Risk Mitigated: Trial stopped early (Week 52 for GFR analysis) due to ethical concerns regarding rapid GFR loss in the placebo arm; this design choice ensures patient safety but limits long-term event accumulation compared to 2-year trials.
• Safety Monitoring: While anti-drug antibodies (ADA) occurred in ~50% of patients, they showed no clinical impact on efficacy or safety; long-term safety data collection continues in open-label extensions.
• Commercial Hurdles: Current sales limitations prevent promotion of full efficacy data (GFR protection) until 2027 full approval.
• Clinical Implementation: Challenge of transitioning clinicians from standard RASi/SGLT2 inhibitor reliance to immediate dual therapy (Atacicept + supportive care).

Management Commentary and Tone:

• Tone: Highly confident, optimistic, and celebratory; described results as a "paradigm shift" and "frame-shift" in nephrology.
• Strategic Narrative: Emphasizes the drug's ability to target the root cause of IgAN (B-cell/plasma cell dysregulation) rather than just hemodynamic management, preventing lifetime kidney failure risk.
• Patient-Centricity: Highlighted the ethical decision to switch placebo patients to active therapy to preserve their kidney function.

Analyst Questions and Answers:

• Comparability to Semeprolimab: Dr. Barrett noted ORIGIN-3 enrolled a sicker, higher-risk population with faster baseline GFR decline, explaining the magnitude of GFR slope differences; validated the dual B-cell/APRIL inhibition strategy across two independent trials.
• Proteinuria vs. GFR: Clarified that significant residual proteinuria can exist alongside stabilized GFR with Atacicept, as the drug prevents immune complex deposition and allows glomerular remodeling, unlike hemodynamic agents.
• Combination Therapy: Confirmed current standard of care remains simultaneous use of Atacicept plus RASi/SGLT2 inhibitors, though future trials may explore Atacicept monotherapy in earlier disease stages.
• Dosing Frequency: Discussed separate molecule properties (TruTacna vs. Teletachycept); Vera is actively evaluating monthly dosing frequency for Atacicept via ongoing dose-ranging studies.
• Steroid Usage: Nephrologists reported a rapid decline in steroid usage due to the availability of safe, effective alternatives like Atacicept.

Other Key Points:

• Trial Design Innovation: ORIGIN-3 introduced a 52-week GFR endpoint as a viable primary endpoint for approval, reducing patient exposure to placebo-induced harm.
• Safety Profile: No deaths, dialysis, or transplants in the Atacicept group; serious adverse events lower than placebo; no opportunistic infections or clinically relevant hypogammaglobulinemia.
• Publication: Pivotal results published simultaneously in the New England Journal of Medicine (NEJM) and presented at the ASN Kidney Week plenary session.